Arcus Biosciences, Inc.RCUSNYSE
Loading
EV to Sales: Discounted ValuationCompressed
Percentile Rank33
3Y CAGR-7.7%
5Y CAGR-9.5%
Year-over-Year Change
Enterprise value to sales ratio
3Y CAGR
-7.7%/yr
vs -23.3%/yr prior
5Y CAGR
-9.5%/yr
Consistent
Acceleration
+15.6pp
Accelerating
Percentile
P33
Within normal range
vs 5Y Ago
0.6x
Contraction
Streak
1 yr
Consecutive growthCompressed
| Period | Value | YoY Change |
|---|---|---|
| 2025 | 9.86 | +103.3% |
| 2024 | 4.85 | -56.3% |
| 2023 | 11.09 | -11.5% |
| 2022 | 12.53 | +72.5% |
| 2021 | 7.26 | -55.3% |
| 2020 | 16.24 | -36.7% |
| 2019 | 25.65 | -29.0% |
| 2018 | 36.13 | -84.0% |
| 2017 | 225.76 | - |
| 2016 | 0.00 | - |